Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer (Q113885243)

From Wikidata
Jump to navigation Jump to search
clinical trial
edit
Language Label Description Also known as
English
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
clinical trial

    Statements

    title
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Camrelizumab (SHR-1210) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (English)
    0 references
    start time
    30 June 2020
    0 references
    end time
    December 2022
    0 references
    number of participants
    396
    0 references
    minimum age
    18 year
    0 references
    maximum age
    75 year
    0 references

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q113885243&oldid=2149031439"